Sitemap > Breaking Research > Infectious Diseases
Displaying 951 - 1000 of 4290 results
- FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration.
- The effect of CD3-specific monoclonal antibody on treating experimental autoimmune myasthenia gravis.
- RNA interference in immune cells by use of osmotic delivery of siRNA.
- Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates.
- Antimalarial activity: a QSAR modeling using CODESSA PRO software.
- Peroxisome proliferator-activated receptor alpha antagonism inhibits hepatitis C virus replication.
- SMM-chemokines: a class of unnatural synthetic molecules as chemical probes of chemokine receptor biology and leads for therapeutic development.
- Synthesis and activity of a new class of pathway-selective estrogen receptor ligands: hydroxybenzoyl-3,4-dihydroquinoxalin-2(1H)-ones.
- MCI-186 (edaravone), a free radical scavenger, attenuates ischemia-reperfusion injury and activation of phospholipase A(2) in an isolated rat lung model after 18 h of cold preservation.
- Macrophage-secreted factors induce adipocyte inflammation and insulin resistance.
- HSV-1-mediated NGF delivery delays nociceptive deficits in a genetic model of diabetic neuropathy.
- Overview of common causes of chronic cough: ACCP evidence-based clinical practice guidelines.
- Chronic cough due to chronic bronchitis: ACCP evidence-based clinical practice guidelines.
- Chronic cough due to nonbronchiectatic suppurative airway disease (bronchiolitis): ACCP evidence-based clinical practice guidelines.
- Chronic cough due to chronic interstitial pulmonary diseases: ACCP evidence-based clinical practice guidelines.
- Cough suppressant and pharmacologic protussive therapy: ACCP evidence-based clinical practice guidelines.
- Potential future therapies for the management of cough: ACCP evidence-based clinical practice guidelines.
- Future directions in the clinical management of cough: ACCP evidence-based clinical practice guidelines.
- Safety and immunogenicity of an oral inactivated whole-cell pseudomonas aeruginosa vaccine administered to healthy human subjects.
- A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection.
- Intranasal exposure to bacterial superantigens induces airway inflammation in HLA class II transgenic mice.
- Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease.
- Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection.
- Human alpha-defensins block papillomavirus infection.
- Intranasal lipopeptide primes lung-resident memory CD8+ T cells for long-term pulmonary protection against influenza.
- Cleavage of intracellular hepatitis C RNA in the virus core protein coding region by deoxyribozymes.
- CCL2/monocyte chemoattractant protein-1 mediates enhanced transmigration of human immunodeficiency virus (HIV)-infected leukocytes across the blood-brain barrier: a potential mechanism of HIV-CNS invasion and NeuroAIDS.
- Novel compounds active against Leishmania major.
- Human immunoglobulin G recognizing fibrinogen-binding surface proteins is protective against both Staphylococcus aureus and Staphylococcus epidermidis infections in vivo.
- Discovery of FabH/FabF inhibitors from natural products.
- Inhibition of human immunodeficiency virus type 1 replication in latently infected cells by a novel IkappaB kinase inhibitor.
- Novel yeast cell-based assay to screen for inhibitors of human cytomegalovirus protease in a high-throughput format.
- In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection.
- Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria.
- Linezolid in prophylaxis against experimental aortic valve endocarditis due to Streptococcus oralis or Enterococcus faecalis.
- In vitro preclinical testing of nonoxynol-9 as potential anti-human immunodeficiency virus microbicide: a retrospective analysis of results from five laboratories.
- In vitro activity of DX-619, a novel des-fluoro(6) quinolone, against a panel of Streptococcus pneumoniae mutants with characterized resistance mechanisms.
- In vitro bactericidal activity of human beta-defensin 3 against multidrug-resistant nosocomial strains.
- In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients.
- CNS viral infection diverts homing of antibody-secreting cells from lymphoid organs to the CNS.
- Synthesis of alpha-substituted fosmidomycin analogues as highly potent Plasmodium falciparum growth inhibitors.
- Respiratory viruses augment the adhesion of bacterial pathogens to respiratory epithelium in a viral species- and cell type-dependent manner.
- Efficient site-specific integration of large transgenes by an enhanced herpes simplex virus/adeno-associated virus hybrid amplicon vector.
- Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody.
- A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques.
- Rectal immunization with rotavirus virus-like particles induces systemic and mucosal humoral immune responses and protects mice against rotavirus infection.
- Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines.
- Scalable generation of high-titer recombinant adeno-associated virus type 5 in insect cells.
- Transient and stable knockdown of the integrase cofactor LEDGF/p75 reveals its role in the replication cycle of human immunodeficiency virus.
- Involvement of multiple epitope-specific cytotoxic T-lymphocyte responses in vaccine-based control of simian immunodeficiency virus replication in rhesus macaques.
< Previous 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 Next >